Close
FINDING CURES TOGETHER<sup>SM</sup>

SU2C Catalyst®

SU2C Catalyst® is a new collaborative initiative intended to leverage all stages of the pharmaceutical, biotechnology, diagnostic, and devices industries to bring new treatments to patients as rapidly as possible. As the Scientific Partner in SU2C Catalyst, the American Association for Cancer Research (AACR) provides scientific oversight and conducts expert peer review and grants administration for SU2C. 

SU2C Catalyst establishes a mechanism through which industry and academic scientists in the cancer community will conduct SU2C collaborative research projects that will deliver significant benefits for patients and society, accelerating the development of new treatments and, where appropriate, combination therapies. 

In October 2017, the AACR and SU2C announced that 10 SU2C Catalyst clinical trials would be launched. The title of each project, with the principal investigator, budget, and agents are: 

  • Combined epigenetic therapy and pembrolizumab for advanced non-small cell lung cancer. Stephen B. Baylin, MD, Van Andel Research Institute; $2.5 million. Combinations: Merck: pembrolizumab (Keytruda®); Astex Pharmaceuticals: guadecitabine; Mirati Therapeutics: mocetinostat. 

  • Targeting VDR to make pancreatic cancer competent for immunotherapy. Daniel D. Von Hoff, MD, Translational Genomics Institute; $2.5 million. Combinations: Merck: pembrolizumab (Keytruda®); AbbVie: paricalcitol (Zemplar®). 

  • DNA repair therapies for ovarian cancer. Alan D. D'Andrea, MD, Dana-Farber Cancer Institute, and Elizabeth M. Swisher, MD, University of Washington; $1 million. Combinations:  Merck: pembrolizumab (Keytruda®); TESARO: niraparib (Zejula™). 

  • Pembrolizumab and radiation therapy to improve outcome in high-risk sarcoma.  David G. Kirsch, MD, PhD, Duke University Medical Center; $2.5 million. Combinations: Merck: pembrolizumab (Keytruda®); radiation therapy.

  • Tumor-infiltrating lymphocyte adoptive T-cell therapy for NSCLC.  Scott J. Antonia, MD, PhD, H. Lee Moffitt Cancer Center; $2.67 million.  Combinations: Bristol-Myers Squibb: nivolumab; Iovance Biotherapeutics: financial support for tumor-infiltrating lymphocytes (TILs); Prometheus Laboratories, Inc.: IL-2. 

  • Combined approaches by immune checkpoint inhibition for hypermutant cancers. Uri Tabori, MD, The Hospital for Sick Children (Toronto); $2.99 million.  Combinations: Bristol-Myers Squibb: nivolumab, ipilimumab. 

  • Reversing primary anti-PD-1 resistance with ipilimumab and nivolumab. Antoni Ribas, MD, PhD, University of California, Los Angeles; $3 million. Combinations:  Bristol-Myers Squibb: nivolumab, ipilimumab.

  • Immunotherapy to prevent progression in multiple myeloma. Irene Ghobrial, MD, Dana-Farber Cancer Institute; $3 million.  Combinations: Bristol-Myers Squibb: nivolumab; lenalidomide. 

  • Overcoming atezolizumab resistance with epigenetic therapy in urothelial cancer.  Peter A. Jones, PhD, DSc, Van Andel Research Institute; $2.99 million. Combinations:  Genentech: atezolizumab (Tecentriq®); Astex Pharmaceuticals: guadecitabine. 

  • Immunotherapy combination strategies in ER-positive metastatic breast cancer. Ingrid Mayer, MD, Vanderbilt University Medical Center; $2.3 million.  Combinations: Genentech: atezolizumab (Tecentriq®), cobimetinib (Cotellic™), idasanutlin. 

Read the news release for further details.

The principles guiding SU2C collaborations with industry are designed to accelerate the pace of groundbreaking translational research that provides new therapies to patients rapidly:

  • Integrity: Industry, academia, and SU2C will act with integrity at all times, putting patients at the center of everything we do.

  • Independence: SU2C and affiliated researchers will maintain independent strategies, activities or information with unbiased scientific overview by its Executive Committee and associated Industry Steering Subcommittees.

  • Transparency: SU2C will be transparent, consistent, and fair when collaborating with industry.

  • Accountability: SU2C is accountable to many stakeholders and thus will not promote, endorse, or favor any particular product.

 

Updated: May 2018